Semaglutide 2.4 mg injection demonstrated significant weight l...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BAGSVÆRD, Denmark, Nov. 5, 2020 /PRNewswire-AsiaNet / -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STE...
Authors: LATEST ASIANET NEWS RELEASES